Brand Strategy and Go-to-Market for Healthcare, MedTech and Dental
Three problems kill healthcare launches. None of them is the product.
A target market defined too wide. A brand that looks like its category. A go to market plan that stalls in rooms you never enter. STR3 fixes all three, in that order. Foundation before facade.
Foundation first. In this order.
First: Target Specificity
We name the buyer before we write a word. Segment, seat and trigger. Which organizations, which roles inside them and what event makes them move now. You get two to three ICP persona profiles with behavioral insight, plus a buyer landscape summary your sales team can act on Monday morning.
Second: Defensible Positioning
We build a brand that survives scrutiny. An AI-enabled Brand Resonance Audit shows how your brand actually reads against five to eight competitors. From there, we build the messaging framework, positioning statement, proof pillars, and voice guide that separate you from Clinical Monotony. Positioning is defensible when it holds up in front of a CFO, not just a design review.
Third: Committee-proof
Go-To-Market
We plan for the room behind the door. A 90-day GTM roadmap, sales messaging, and objection handling built for the Hidden Buying Committee- the six seats that quietly decide deals: Legal, IT, Procurement, Finance, Clinical Leadership, and Regulatory/Quality. Plus a KPI framework so you know what is working by week four, not quarter four.
What does an engagement cost?
Engagements are scoped to the decision in front of you, and they begin at $30,000. The right question is not the price of the strategy, it is the cost of the stalled launch it prevents.
What is the difference between
a fractional CMO and an agency?
An agency executes briefs. A fractional CMO owns the strategy behind them, embedded inside your leadership conversations and carries accountability for the outcome. STR3. embeds at that level, so the senior person who scopes the work is the one doing it.
The Mini Market Positioning Audit
Start with two weeks, not a quarter.
The smallest serious project we run. Fixed scope, fixed timeline, one fixed number, and a report you keep whether or not we ever speak again.
$5,500
10 business days.
Founder-led, healthcare only. Start date confirmed at booking.
01 Founder-led, healthcare only. Start date confirmed at booking
02 Positioning gap map, one visual matrix
03 Differentiation brief, three to five priority vectors
04 Final audit report with recommended next steps
Every audit finding feeds directly into the larger engagements below. If the audit surfaces a gap worth fixing, you start the bigger work already knowing where to aim. If it confirms your position holds, you spent two weeks verifying your foundation instead of a quarter guessing.
When the gap is bigger than two weeks.
Brand Clarity Sprint
Six weeks. Full Brand Resonance Audit, competitive map, messaging framework, voice guide. For teams with fuzzy positioning, pre-raise, pre-launch or post-pivot. $30,000.
GTM Launch Accelerator
Ten weeks. Market entry readiness, 90-day roadmap, objection handling, KPI framework. For teams entering or expanding in the U.S. market. $45,000.
Brand + GTM Combo
Fourteen weeks. The full foundation, brand system through launch roadmap, sequenced so each layer holds the next. $65,000.
Every engagement is founder-led and healthcare only. No account handoffs, no junior team behind the curtain.
Brand and GTM Clarity, built by someone who has sat in your seat.
STR3 is led by a founder with 20 years in senior marketing and commercial roles across implant systems, digital dentistry and dental imaging, on both sides of the Atlantic. That includes validating hundreds of healthcare startups through MassChallenge and launching products from concept through FDA clearance to market. The frameworks are new. The scar tissue is not.
Two weeks from now you could know exactly where you stand.
If one of the three problems on this page sounded familiar, the audit answers whether it is costing you deals and where the opening is. Fixed scope, fixed price, a report you keep either way. If you would rather talk it through first, that works too.
You probably recognize at least one of these.
You're selling to everyone.
Your deck says hospitals, DSOs, labs and startups. Your sales team hears all of it and prioritizes none of it. When the target is everyone, the message is average, and average does not survive a healthcare buying process.
You look like your category.
Blue gradients, stock clinicians, the same five words as the booth next to yours. We call it Clinical Monotony, the visual and verbal sameness that makes healthcare brands interchangeable. Buyers cannot choose what they cannot tell apart.
Your deals die in rooms you never enter.
The demo went well. The champion was sold. Then the deal went quiet because Legal, IT, Procurement, Finance, Clinical Leadership, and Regulatory had questions your brand never answered. Most go-to-market plans are built for the buyer in the room, not the committee behind the door.
These are not three problems. They are one.
20X
Research from the LinkedIn B2B Institute with Bain puts numbers on what most commercial leaders feel. Buying groups are 20 times more likely to purchase when everyone in the group already knows the brand. About half of the buying influence sits with people the seller never meets. And 81 percent of buyers arrive with a day-one shortlist of roughly four vendors, which the winner usually comes from.
That is why targeting, brand and go-to-market fail together. If the target is fuzzy, the brand cannot be specific. If the brand is not specific, the committee has no reason to trust it. If the committee does not trust it, the go-to-market plan is a schedule of meetings that go nowhere.
The industry has a word for the fix. We use Buyability, a brand's defensibility across the full buying committee. Not more visibility. Defensibility, for every seat that can say no.